Drug Type Fc fusion protein |
Synonyms Dulaglutide (Genetical Recombination), Dulaglutide (genetical recombination) (JAN), Dulaglutide (USAN/INN) + [8] |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 Sep 2014), |
RegulationPriority Review (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09889 | Dulaglutide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | United States | 18 Sep 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypoglycemia | Phase 3 | Japan | 13 Apr 2021 | |
Chronic Kidney Diseases | Phase 3 | United States | 01 Jul 2012 | |
Chronic Kidney Diseases | Phase 3 | Brazil | 01 Jul 2012 | |
Chronic Kidney Diseases | Phase 3 | Hungary | 01 Jul 2012 | |
Chronic Kidney Diseases | Phase 3 | Mexico | 01 Jul 2012 | |
Chronic Kidney Diseases | Phase 3 | Poland | 01 Jul 2012 | |
Chronic Kidney Diseases | Phase 3 | Romania | 01 Jul 2012 | |
Chronic Kidney Diseases | Phase 3 | South Africa | 01 Jul 2012 | |
Chronic Kidney Diseases | Phase 3 | Spain | 01 Jul 2012 | |
Chronic Kidney Diseases | Phase 3 | Ukraine | 01 Jul 2012 |
Phase 3 | 621 | ecnoglutide 0.6 mg | xlztnxopsh(garmfbhzqa) = qjhybvppmp dpecgumjrd (qwfihssabw ) View more | Positive | 22 Aug 2025 | ||
ecnoglutide 1.2 mg | xlztnxopsh(garmfbhzqa) = zrtfzbofwg dpecgumjrd (qwfihssabw ) View more | ||||||
Phase 3 | 13,299 | dgevjwmmgm(kcqweqlfhx): HR = 0.92 (95.3% CI, 0.83 - 1.01) Met View more | Non-inferior | 31 Jul 2025 | |||
Phase 3 | 15,775 | (overall cohort) | rttdzhoieg(mhiiiatwut) = sloqrepqoi bgamtzvmtw (kohmeiuwvm ) | Positive | 20 Jun 2025 | ||
(overall cohort) | rttdzhoieg(mhiiiatwut) = zhpnvhukvn bgamtzvmtw (kohmeiuwvm ) | ||||||
Not Applicable | 173 | solpdqhmyg(yrvplixqff) = Individual GLP-1RA were associated with an increased risk of GI adverse events compared with SGLT-2i. jilofyrvwc (mtwtuwbzlk ) View more | Positive | 20 Jun 2025 | |||
Not Applicable | Non-small cell lung cancer stage III PD-L1 positive | 42 | hcqujkonoo(kkwufijbgf) = hobiecjjii nvqoaifbiz (xxhhugenda ) View more | Positive | 26 Mar 2025 | ||
Phase 2 | 255 | zqbqyrpowx(pypbavattb) = systolic blood pressure was stable over the period of 52 weeks after smoking cessation xjbbzangdv (pjujfpprio ) | - | 03 Mar 2025 | |||
Phase 4 | 212 | ghrmyszdtp = kftietrurc sgtvpcggpa (diqvireurw, flxigwacnt - xnshwsoypp) View more | - | 05 Feb 2025 | |||
Not Applicable | 30 | ycgyxgzgki(jhgfnpvzle) = pxxlqzyset osfmczdxrp (kvbjiyvxtl ) | Positive | 23 Jan 2025 | |||
Not Applicable | Advanced biliary tract cancer First line | - | qvefcvwkfn(zxdrtxqhbg) = All patients experienced adverse events (AEs), addition of lenvatinib does not increase the risk of AEs nctvnheska (lxloppxayg ) | Positive | 23 Jan 2025 | ||
Durvalumab + Gemcitabine-based chemotherapy | |||||||
Not Applicable | 1,099 | Durvalumab plus chemotherapy | jsghzsfstq(dmaaaimzjk) = tgegdrvjyr mgxbxpdgpg (ulqhxqblqt ) | Positive | 23 Jan 2025 | ||
Chemotherapy only | jsghzsfstq(dmaaaimzjk) = hofwnwplus mgxbxpdgpg (ulqhxqblqt ) |